PURPOSE: Seliciclib is a small-molecule cyclin-dependent kinase inhibitor, which has been reported to induce apoptosis and cell cycle arrest in EBV-negative nasopharyngeal carcinoma cell lines. Because most nasopharyngeal carcinoma patients harbor EBV, we proceeded to evaluate the cytotoxic effects of seliciclib in EBV-positive nasopharyngeal carcinoma models. EXPERIMENTAL DESIGN: Cytotoxicity of seliciclib was investigated in the EBV-positive cell line C666-1 and the C666-1 and C15 xenograft models. Caspase activities and cell cycle analyses were measured by flow cytometry. Efficacy of combined treatment of seliciclib with radiation therapy was also evaluated. RESULTS: Seliciclib caused significant cytotoxicity in the C666-1 cells in a time- and dose-dependent manner, with accumulation of cells in both sub-G(1) and G(2)-M phases, indicative of apoptosis and cell cycle arrest, respectively. Caspase-2, -3, -8, and -9 activities were all increased, with caspase-3 being the most significantly activated at 48 h after treatment. These cells also showed a reduction of Mcl-1 mRNA and protein levels. Combined treatment of seliciclib with radiation therapy showed a synergistic interaction with enhanced cytotoxicity in C666-1 cells and delayed repair of double-strand DNA breaks. For in vivo models, significant delays in tumor growth were observed for both C666-1 and C15 tumors, which were associated with enhanced apoptosis as determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and immunohistochemistry analyses. CONCLUSIONS: Seliciclib enhanced the antitumor efficacy of radiation therapy in EBV-positive nasopharyngeal carcinoma, characterized by G(2)-M arrest, and apoptosis, associated with an induction in caspase activity. This process is mediated by reduction in Mcl-1 expression and by attenuation of double-strand DNA break repair.
PURPOSE:Seliciclib is a small-molecule cyclin-dependent kinase inhibitor, which has been reported to induce apoptosis and cell cycle arrest in EBV-negative nasopharyngeal carcinoma cell lines. Because most nasopharyngeal carcinomapatients harbor EBV, we proceeded to evaluate the cytotoxic effects of seliciclib in EBV-positive nasopharyngeal carcinoma models. EXPERIMENTAL DESIGN:Cytotoxicity of seliciclib was investigated in the EBV-positive cell line C666-1 and the C666-1 and C15 xenograft models. Caspase activities and cell cycle analyses were measured by flow cytometry. Efficacy of combined treatment of seliciclib with radiation therapy was also evaluated. RESULTS:Seliciclib caused significant cytotoxicity in the C666-1 cells in a time- and dose-dependent manner, with accumulation of cells in both sub-G(1) and G(2)-M phases, indicative of apoptosis and cell cycle arrest, respectively. Caspase-2, -3, -8, and -9 activities were all increased, with caspase-3 being the most significantly activated at 48 h after treatment. These cells also showed a reduction of Mcl-1 mRNA and protein levels. Combined treatment of seliciclib with radiation therapy showed a synergistic interaction with enhanced cytotoxicity in C666-1 cells and delayed repair of double-strand DNA breaks. For in vivo models, significant delays in tumor growth were observed for both C666-1 and C15 tumors, which were associated with enhanced apoptosis as determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and immunohistochemistry analyses. CONCLUSIONS:Seliciclib enhanced the antitumor efficacy of radiation therapy in EBV-positive nasopharyngeal carcinoma, characterized by G(2)-M arrest, and apoptosis, associated with an induction in caspase activity. This process is mediated by reduction in Mcl-1 expression and by attenuation of double-strand DNA break repair.
Authors: Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Benjamin T Houseman; Eli Zunder; Andrei Goga; Nathanael S Gray; Brian Pollok; Scott A Oakes; C David James; Kevan M Shokat; William A Weiss; Qi-Wen Fan Journal: Proc Natl Acad Sci U S A Date: 2012-07-16 Impact factor: 11.205
Authors: C Delehouzé; K Godl; N Loaëc; C Bruyère; N Desban; N Oumata; H Galons; T I Roumeliotis; E G Giannopoulou; J Grenet; D Twitchell; J Lahti; N Mouchet; M-D Galibert; S D Garbis; L Meijer Journal: Oncogene Date: 2013-12-09 Impact factor: 9.867
Authors: Katie L Martin; Grace A Hill; Rob R Klein; Deborah G Arnett; Randy Burd; Kirsten H Limesand Journal: PLoS One Date: 2012-12-07 Impact factor: 3.240
Authors: Mario Federico; Catherine E Symonds; Luigi Bagella; Flavio Rizzolio; Daniele Fanale; Antonio Russo; Antonio Giordano Journal: Mol Cancer Date: 2010-08-04 Impact factor: 27.401
Authors: Justin P Williams; Inki Kim; Emma Ito; Wei Shi; Shijun Yue; Lillian L Siu; John Waldron; Brian O'Sullivan; Kenneth W Yip; Fei-Fei Liu Journal: PLoS One Date: 2014-05-22 Impact factor: 3.240
Authors: Michelle Lenarduzzi; Angela B Y Hui; Nehad M Alajez; Wei Shi; Justin Williams; Shijun Yue; Brian O'Sullivan; Fei-Fei Liu Journal: PLoS One Date: 2013-01-15 Impact factor: 3.240